This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.
|Original language||English (US)|
|Number of pages||32|
|Journal||JNCCN Journal of the National Comprehensive Cancer Network|
|State||Published - Apr 1 2017|
ASJC Scopus subject areas